A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease

S

Senju Pharmaceutical

Status and phase

Completed
Phase 3

Conditions

Dry Eye Syndromes

Treatments

Drug: Placebo
Drug: SJP-0035 0.001%

Study type

Interventional

Funder types

Industry

Identifiers

NCT03527212
SJP-0035/3-01

Details and patient eligibility

About

A double-masked, randomized, multi-center, placebo-controlled, parallel-group study in adult patients with Dry Eye Disease (DED). Patients will be randomly assigned to receive either SJP-0035 0.001% or placebo

Full description

There are currently no approved products available anywhere worldwide for the treatment of Dry Eye Disease (DED) that directly affect the corneal epithelium. This study will evaluate the safety and efficacy of SJP-0035 0.001%, compared with a placebo, on corneal healing. Patients meeting the requirements of the inclusion/exclusion criteria will administer 1 drop of the study drug/placebo 4 times per day for 4 weeks.

Enrollment

329 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Signed informed consent form (ICF).
  • Has Dry Eye Disease (DED) with moderate to severe corneal fluorescein staining in both eyes.
  • Has blurred vision caused by DED in both eyes.
  • Women of childbearing potential must have negative serum pregnancy test results at Screening and Randomization and agree to use effective contraception throughout the study; post-menopausal women must have negative serum pregnancy test results at Screening and Randomization.
  • Male participants must agree to use an acceptable form of contraception (i.e. a condom plus spermicide) and to refrain from sperm donation throughout the study.

Exclusion criteria

  • Has any corneal stromal or endothelial abnormalities in either eye.
  • Has any active or chronic allergic, bacterial or viral infection of ocular adnexa and eye structures in either eye.
  • Has had eye surgery (including cataract, vitreous or eyelid surgery) in either eye within the last 28 days prior to first dose of study drug.
  • Has had refractive surgery (including eye surface laser surgery) in either eye within the last 180 days prior to first dose of study drug.
  • Has used any eye medication in either eye within 14 days prior to first dose of study drug, or is anticipated to require such medications during the study. Preservative-free artificial tears may be used up to 72 hours prior to the first dose in either eye.
  • Is a contact lens wearer and cannot discontinue use in both eyes from Screening through the duration of the study.
  • Has previously received SJP-0035 (study drug) in either eye.
  • Currently has punctal occlusions, of any type, inserted into both superior and inferior puncta in either eye at Screening through the duration of the study.

Other protocol-defined inclusion/exclusion criteria could apply.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

329 participants in 2 patient groups, including a placebo group

SJP-0035 0.001% (ophthalmic solution)
Experimental group
Treatment:
Drug: SJP-0035 0.001%
Placebo (ophthalmic solution)
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

23

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems